NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

Lei Lei Wu

News Reporter

Bay Area biotech NGM Biopharmaceuticals reported Thursday afternoon that its drug candidate for non-alcoholic steatohepatitis, or NASH, improved results on a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

NGM tabled its NASH pro­gram in 2021 af­ter a key tri­al fail­ure. Now it’s re­port­ing suc­cess in a sec­ond study

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study